Literature DB >> 15909291

Flexible Bayesian methods for cancer phase I clinical trials. Dose escalation with overdose control.

Mourad Tighiouart1, André Rogatko, James S Babb.   

Abstract

We examine a large class of prior distributions to model the dose-response relationship in cancer phase I clinical trials. We parameterize the dose-toxicity model in terms of the maximum tolerated dose (MTD) gamma and the probability of dose limiting toxicity (DLT) at the initial dose rho(0). The MTD is estimated using the EWOC (escalation with overdose control) method of Babb et al. We show through simulations that a candidate joint prior for (rho0,gamma) with negative a priori correlation structure results in a safer trial than the one that assumes independent priors for these two parameters while keeping the efficiency of the estimate of the MTD essentially unchanged. Copyright 2005 John Wiley & Sons, Ltd

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15909291     DOI: 10.1002/sim.2106

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  29 in total

1.  Integrating the escalation and dose expansion studies into a unified Phase I clinical trial.

Authors:  Alexia Iasonos; John O'Quigley
Journal:  Contemp Clin Trials       Date:  2016-07-05       Impact factor: 2.226

Review 2.  Statistical controversies in clinical research: requiem for the 3 + 3 design for phase I trials.

Authors:  X Paoletti; M Ezzalfani; C Le Tourneau
Journal:  Ann Oncol       Date:  2015-06-18       Impact factor: 32.976

3.  Continual Reassessment and Related Dose-Finding Designs.

Authors:  John O'Quigley; Mark Conaway
Journal:  Stat Sci       Date:  2010       Impact factor: 2.901

4.  A likelihood-based approach for computing the operating characteristics of the 3+3 phase I clinical trial design with extensions to other A+B designs.

Authors:  Cody Chiuzan; Elizabeth Garrett-Mayer; Sharon D Yeatts
Journal:  Clin Trials       Date:  2014-10-27       Impact factor: 2.486

5.  Dose Finding for Drug Combination in Early Cancer Phase I Trials using Conditional Continual Reassessment Method.

Authors:  Márcio Augusto Diniz; Mourad Tighiouart
Journal:  J Biom Biostat       Date:  2017-11-27

6.  Safety and efficacy of oral panobinostat plus chemotherapy in patients aged 65 years or younger with high-risk acute myeloid leukemia.

Authors:  Daniel J DeAngelo; Alison R Walker; Richard F Schlenk; Jorge Sierra; Bruno C Medeiros; Enrique M Ocio; Christoph Röllig; Stephen A Strickland; Felicitas Thol; Sue-Zette Valera; Kohinoor Dasgupta; Noah Berkowitz; Robert K Stuart
Journal:  Leuk Res       Date:  2019-08-01       Impact factor: 3.156

7.  A Bayesian adaptive design for cancer phase I trials using a flexible range of doses.

Authors:  Mourad Tighiouart; Galen Cook-Wiens; André Rogatko
Journal:  J Biopharm Stat       Date:  2017-10-06       Impact factor: 1.051

8.  A phase Ib dose-escalation study of the MEK inhibitor trametinib in combination with the PI3K/mTOR inhibitor GSK2126458 in patients with advanced solid tumors.

Authors:  J E Grilley-Olson; P L Bedard; A Fasolo; M Cornfeld; L Cartee; A R Abdul Razak; L-A Stayner; Y Wu; R Greenwood; R Singh; C B Lee; J Bendell; H A Burris; G Del Conte; C Sessa; J R Infante
Journal:  Invest New Drugs       Date:  2016-07-23       Impact factor: 3.850

9.  A phase 1, single centre, open label, escalating dose study to assess the safety, tolerability and immunogenicity of a therapeutic human papillomavirus (HPV) DNA vaccine (AMV002) for HPV-associated head and neck cancer (HNC).

Authors:  J Chandra; W P Woo; N Finlayson; H Y Liu; M McGrath; R Ladwa; M Brauer; Y Xu; S Hanson; B Panizza; I H Frazer; Sandro V Porceddu
Journal:  Cancer Immunol Immunother       Date:  2020-09-12       Impact factor: 6.968

10.  A Bayesian seamless phase I-II trial design with two stages for cancer clinical trials with drug combinations.

Authors:  José L Jiménez; Sungjin Kim; Mourad Tighiouart
Journal:  Biom J       Date:  2020-03-09       Impact factor: 2.207

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.